Background: Hip fracture care delivery varies between hospitals, which might explain variations in patient outcomes and health costs. The aim of this study was to identify hospital-level organisational factors associated with long-term patient outcomes and costs after hip fracture., Methods: REDUCE was a record-linkage cohort study in which national databases for all patients aged 60 years and older who sustained a hip fracture in England and Wales were linked with hospital metrics from 18 organisational data sources. Multilevel models identified organisational factors associated with the case-mix adjusted primary outcomes: cumulative all-cause mortality, days spent in hospital, and inpatient costs over 365 days after hip fracture., Findings: Between April 1, 2016, and March 31, 2019, 178 757 patients with an index hip fracture were identified from 172 hospitals in England and Wales. 126 278 (70·6%) were female, 52 479 (29·4%) were male, and median age was 84 years (IQR 77-89) in England and 83 years (77-89) in Wales. 365 days after hip fracture, 50 354 (28·2%) patients had died. Patients spent a median 21 days (IQR 11-41) in hospital, incurring costs of £14 642 (95% CI 14 600-14 683) per patient, ranging from £10 867 (SD 5880) to £23 188 (17 223) between hospitals. 11 organisational factors were independently associated with mortality, 24 with number of days in hospital, and 25 with inpatient costs. Having all patients assessed by an orthogeriatrician within 72 h of admission was associated with a mean cost saving of £529 (95% CI 148-910) per patient and a lower 365-day mortality (odds ratio 0·85 [95% CI 0·76-0·94]). Consultant orthogeriatrician attendance at clinical governance meetings was associated with cost savings of £356 (95% CI 188-525) and 1·47 fewer days (95% CI 0·89-2·05) in the hospital in the 365 days after hip fracture per patient. The provision of physiotherapy to patients on weekends was associated with a cost saving of £676 (95% CI 67-1285) per patient and with 2·32 fewer days (0·35-4·29) in hospital in the 365 days after hip fracture., Interpretation: Multiple, potentially modifiable hospital-level organisational factors associated with important clinical outcomes and inpatient costs were identified that should inform initiatives to improve the effectiveness and efficiency of hip fracture services., Funding: Versus Arthritis., Competing Interests: Declaration of interests PB reports funding by the European Commission (grant reference H2020-MSCA- ITN-2017 grant agreement identifier 7651141) and from the Hungarian Ministry of Innovation and Technology (grant reference 1783-3/2018/FEKUTSTRAT and TKP2020-IKA-02). AJu reports grants from National Institute for Health and Care Research (NIHR), Health Data Research UK, Versus Arthritis, Healthcare Quality Improvement Partnership, Royal College of Physicians, and Tommy's Health Foundation; chairs a data monitoring committee (NIHR Health Technology Assessment of the DISC trial at the University of Leicester, Leicester, UK) and a trial steering committee (NIHR Health Technology Assessment of the Gentle Years Yoga Trial, Newcastle University, Newcastle, UK); is a member of a steering committee at Nuffield Foundation (Multilevel Integrated Data for musculoskeletal health intelligence and Actions, University of Keele, Keele, UK); is a data monitoring committee member at Robotic Arthroplasty (RACER trial, Clinical Trials Unit, University of Warwick, Warwick, UK); is a sub-panel member of the NIHR Programme Grants for Applied Research programme; is on the Versus Arthritis Health Subcommittee; is co-chair of the Versus Arthritis Research Expert group; and is a member of the Nuffield Foundation Oliver Bird Fund Expert Panel. AJo is the clinical lead for the National Hip Fracture Database at the Royal College of Physicians, London, UK. JG reports an educational contract with Stryker that does not entail any relationships or activities that could have influenced the submitted work. TC is a member of the National Hip Fracture Database Advisory Board; has design and educational contracts with Stryker, Acumed, and Swemac; was a representative of the British Orthopaedic Association; previously sat on the board of the Falls and Fragility Fracture Audit Project (which includes the National Hip Fracture Database); and helped set up and perform British Orthopaedic Association multidisciplinary peer reviews for hip fractures. XLG reports funding from the NIHR Health Technology Assessment Programme; multiple other grants from NIHR for specific projects unrelated to this work; and consultancy fees from Johnson & Johnson and Stryker. MKJ reports honoraria, unrestricted research grants, and travel or subsistence expenses from Amgen, Consilient Health, Kyowa Kirin Hakin, UCB, AbbVie, Sanofi, and Besin Healthcare; participation in the committees or boards of Regeneron, International Osteoporosis Foundation Capture the Fracture Steering Committee, Fracture Liaison Service Database of England and Wales, and medical advisory board of Brittle Bone Society and Fibrous Dysplasia Support Society UK. ECB reports funding from the UK Prevention Research Partnership (Violence, Health and Society; grant reference MR-VO49879/1), the British Heart Foundation, the Scottish Government Health and Social Care Directorates, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Health and Social Care Research and Development Division (Welsh Government), Medical Research Council, NIHR, Natural Environment Research Council, Public Health Agency (Northern Ireland), the Health Foundation, and the Wellcome Trust. YB-S reports book royalties from Oxford University Press and Wiley; consulting fees from Human Centric Drug Discovery; and is a member of the trial steering committee of the SIMPLIFIED trial. EMRM reports research funding from CeramTec UK, NIHR, Medical Research Council, and the Healthcare Quality Improvement Partnership; is a steering group committee advisor for an NIHR Health Services and Delivery Research grant and an NIHR Health Technology Assessment grant; and a committee member for the NIHR Research for Patient Benefit funding scheme since 2017 and NIHR Programme Grant for Applied Research funding scheme since 2023. CLG reports research grants from Wellcome Trust, Royal Osteoporosis Society, Chan Zuckerberg Donor Advised Fund, and Versus Arthritis; and is a Chair of the National Osteoporosis Guideline Group and a member of the Royal College of Physicians Falls and Fragility Fracture Scientific committee. RP reports funding from CeramTec UK on an unrelated study and after completion of the analyses for the present Article., (Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)